Prognostic variables in newly diagnosed children and adolescents with acute myeloid leukemia: Children's Cancer Group Study 213

被引:31
作者
Wells, RJ
Arthur, DC
Srivastava, A
Heerema, NA
Le Beau, M
Alonzo, TA
Buxton, AB
Woods, WG
Howells, WB
Benjamin, DR
Betcher, DL
Buckley, JD
Feig, SA
Kim, T
Odom, LF
Ruymann, FB
Smithson, WA
Tannous, R
Whitt, JK
Wolff, L
Tjoa, T
Lampkin, BC
机构
[1] Univ Cincinnati, Med Ctr, Childrens Hosp Res Fdn, Cincinnati, OH 45267 USA
[2] NCI, Pathol Lab, Bethesda, MD 20892 USA
[3] Univ Cincinnati, Ctr Med, Cincinnati, OH USA
[4] Parker Hughes Inst, St Paul, MN USA
[5] Univ Chicago, Chicago, IL 60637 USA
[6] Univ S Carolina, S Carolina Canc Ctr, Columbia, SC 29208 USA
[7] Univ So Calif, Keck Sch Med, Los Angeles, CA USA
[8] Childrens Hosp, Med Ctr, Seattle, WA USA
[9] Mayo Med Ctr, Rochester, MN USA
[10] Univ Calif Los Angeles, Los Angeles, CA USA
[11] Abbott NW Hosp, Virginia Piper Canc Inst, Minneapolis, MN 55407 USA
[12] Univ Colorado, Ctr Canc, Denver, CO 80202 USA
[13] Childrens Hosp, Denver, CO 80218 USA
[14] Childrens Hosp Columbus, Columbus, OH USA
[15] Ohio State Univ, Columbus, OH 43210 USA
[16] Univ Iowa, Iowa City, IA USA
[17] Univ N Carolina, Chapel Hill, NC USA
[18] Oregon Hlth & Sci Univ, Doernbecher Childrens Hosp, Portland, OR 97201 USA
[19] Childrens Oncol Grp, Operat Ctr, Arcadia, CA USA
关键词
childhood acute myeloid leukemia; prognostic factors;
D O I
10.1038/sj.leu.2402390
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The objective of this study was to identify biologic parameters that were associated with either exceptionally good or poor outcome in childhood acute myeloid leukemia (AML). Among the children with AML who entered Children's Cancer Group trial 213, 498 patients without Down syndrome or acute promyelocytic leukemia (APL) comprise the basis for this report. Univariate comparisons of the proportion of patients attaining complete remission after induction (CR) indicate that, at diagnosis, male gender, low platelet count (less than or equal to20 000/mul), hepatomegaly, myelodysplastic syndrome (MDS), French-American-British (FAB) category M5, high (>15%) bone marrow BM blasts on day 14 of the first course of induction, and +8 are associated with lower CR rates, while abnormal 16 is associated with a higher CR rate. Multivariate analysis suggests high platelet count at diagnosis (>20 000/mul), absence of hepatomegaly, less than or equal to15% day 14 BM blast percentage, and abnormal 16 are independent prognostic factors associated with better CR. Univariate analysis demonstrated a significant favorable relationship between platelet count at diagnosis (>20 000/mul), absence of hepatomegaly, low percentage of BM blasts (less than or equal to15%), and abnormal 16 with overall survival. Absence of hepatomegaly, less than or equal to15% day 14 BM blast percentage, and abnormal 16 were determined to be independent prognostic factors associated with better survival.
引用
收藏
页码:601 / 607
页数:7
相关论文
共 28 条
[21]  
RAVINDRANATH Y, 1992, BLOOD, V80, P2210
[22]  
SCHIFFER CA, 1996, CANC MED, P2617
[23]   Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia [J].
Smith, M ;
Arthur, D ;
Camitta, B ;
Carroll, AJ ;
Crist, W ;
Gaynon, P ;
Gelber, R ;
Heerema, N ;
Korn, EL ;
Link, M ;
Murphy, S ;
Pui, CH ;
Pullen, J ;
Reaman, G ;
Sallan, SE ;
Sather, H ;
Shuster, J ;
Simon, R ;
Trigg, M ;
Tubergen, D ;
Uckun, F ;
Ungerleider, R .
JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (01) :18-24
[24]   LONG-TERM SURVIVAL IN ACUTE MYELOGENOUS LEUKEMIA - A 2ND FOLLOW-UP OF THE 4TH INTERNATIONAL WORKSHOP ON CHROMOSOMES IN LEUKEMIA [J].
SWANSBURY, GJ ;
LAWLER, SD ;
ALIMENA, G ;
ARTHUR, D ;
BERGER, R ;
VANDENBERGHE, H ;
BLOOMFIELD, CD ;
DELACHAPPELLE, A ;
DEWALD, G ;
GARSON, OM ;
HAGEMEIJER, A ;
MITELMAN, F ;
ROWLEY, JD ;
SAKURAI, M .
CANCER GENETICS AND CYTOGENETICS, 1994, 73 (01) :1-7
[25]   TREATMENT OF NEWLY-DIAGNOSED CHILDREN AND ADOLESCENTS WITH ACUTE MYELOID-LEUKEMIA - A CHILDRENS CANCER GROUP-STUDY [J].
WELLS, RJ ;
WOODS, WG ;
BUCKLEY, JD ;
ODOM, LF ;
BENJAMIN, D ;
BERNSTEIN, I ;
BETCHER, D ;
FEIG, S ;
KIM, T ;
RUYMANN, F ;
SMITHSON, W ;
SRIVASTAVA, A ;
TANNOUS, R ;
BUCKLEY, CM ;
WHITT, JK ;
WOLFF, L ;
LAMPKIN, BC .
JOURNAL OF CLINICAL ONCOLOGY, 1994, 12 (11) :2367-2377
[26]   A simple, robust, validated and highly predictive index for the determination of risk-directed therapy in acute myeloid leukaemia derived from the MRC AML 10 trial [J].
Wheatley, K ;
Burnett, AK ;
Goldstone, AH ;
Gray, RG ;
Hann, IM ;
Harrison, CJ ;
Rees, JKH ;
Stevens, RF ;
Walker, H .
BRITISH JOURNAL OF HAEMATOLOGY, 1999, 107 (01) :69-79
[27]   CORRELATION OF CHROMOSOME-ABNORMALITIES WITH PATIENT CHARACTERISTICS, HISTOLOGIC SUBTYPE, AND INDUCTION SUCCESS IN CHILDREN WITH ACUTE NONLYMPHOCYTIC LEUKEMIA [J].
WOODS, WG ;
NESBIT, ME ;
BUCKLEY, J ;
LAMPKIN, BC ;
MCCREADIE, S ;
KIM, TH ;
PIOMELLI, S ;
KERSEY, JH ;
FEIG, S ;
BERNSTEIN, I ;
HAMMOND, D .
JOURNAL OF CLINICAL ONCOLOGY, 1985, 3 (01) :3-11
[28]   Timed-sequential induction therapy improves postremission outcome in acute myeloid leukemia: A report from the Children's Cancer Group [J].
Woods, WG ;
Kobrinsky, N ;
Buckley, JD ;
Lee, JW ;
Sanders, J ;
Neudorf, S ;
Gold, S ;
Barnard, DR ;
DeSwarte, J ;
Dusenbery, K ;
Kalousek, D ;
Arthur, DC ;
Lange, BJ .
BLOOD, 1996, 87 (12) :4979-4989